$NVLX According to the American cancer Society, in the US alone, approximately 45,000 new cases of pancreatic cancer are expected to be diagnosed this year and about 38,000 people are predicted to die from the disease; it is the leading cause of cancer deaths in the US and worldwide. Often pancreatic cancer is not diagnosed until it has reached an advanced stage. By this time, the cancer cannot be removed surgically, is often resistant to radiation therapy or chemotherapy, and has spread (metastasized) to other organs in the body. Because of this, the average survival of patients with advanced, inoperable pancreatic cancer is given in terms of weeks or months, not years.Nuvilex’s pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and widely used anticancer drug ifosfamide.In a Phase I/II open-label, prospective, single-arm clinical trial, the live-cell encapsulation/ifosfamide combination was used to treat patients with advanced, inoperable pancreatic cancer. Fifty-one patients were originally “screened” for the trial; of these, 17 were enrolled in the study. Other patients were excluded from enrollment for therapy because of previous chemotherapy, previous pancreatic surgery, poor overall health, unwillingness to participate, or death prior to the start of the trial. Of the 17 patients initially enrolled in the study, 14 were ultimately treated. Results obtained in the clinical trial were compared with historical data for gemcitabine and included: median survival time of 44 weeks (after diagnosis) with the cell encapsulation/ifosfamide treatment as compared to 28 weeks with gemcitabine; doubling of the one-year survival rate – 36% with our treatment vs. 18% with gemcitabine; tumor volume was reduced 25-50% in 4 of the 14 treated patients and remained stable in the remaining patients; no serious drug-related side effects with the encapsulated cell/ifosfamide treatment whereas serious and very serious side effects were reported with gemcitabine; the lack of serious side effects using our treatment is probably related to the use of “lower than normal” doses of ifosfamide; limited side effects and reduced cancer pain intensity led to a generally increased ‘quality of life” for the majority of patients. In a “worst case” scenario, some clinical benefit was seen in 50% of patients and in a “best case” scenario, this number increased to 71%; none of the patients who experienced a clinical benefit required and increase in their pain medication.
$NVLX According to the American cancer Society, in the US
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Food Trends Tease: 2027 sofi™ Awards' 75 Finalists
The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...
Continue Reading
Kansai Medical Ushers in New Era of Cancer Research
Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...
Continue Reading
Standex's New Financial Lead: Stoddard Takes Helm
New Financial Captain Aboard Standex's Ship Alright, here's something that'll have investors nodding along with interest: Standex International has just named Samantha L. Stoddard as their incoming Chief Financial Officer and Treasurer, effective December 1, 2026. Now, Standex isn't some scrappy upstart. We're talking about a veteran manufacturer intricately working...
Continue Reading
Baidu Faces Class Action: Investors Push Against Fraud Allegations
Baidu Under Fire for Alleged Misleading Statements Here's a fresh slice of drama straight outta the corporate trenches: Baidu, Inc. (NASDAQ: BIDU) finds itself tangled in a securities fraud lawsuit that’s causing a ruckus across investor circles. Schall, Brown & Schwartz LLP, those heavyweight gladiators in shareholder rights, are calling on grieved investors to step up...
Continue Reading
Encompass Health: Leader in Rehabilitation Again in 2026
Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...
Continue Reading
FLUX 3 Max Launches with Unmatched Speed and Quality
A Lightning Fast Leap in Video Generation It's all eyes on FLUX 3 Max today. You can almost hear the gasps of 'wow' in the generative media crowd. Why? Because this new weapon in the video gen arsenal, dreamed up by fal and Black Forest Labs, is slicing through the old speed limits like a blistering comet. Now, don't get me wrong. Seeds don't grow overnight, and neither...
Continue Reading
GELITA Showcases Collagen Innovations at SupplySide 2026
Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...
Continue Reading
TilePix Expands into Walmart with Nail-Free Decor Launch
TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...
Continue Reading
Steel Dynamics' Q3 2026: Record Shipments Boost Profits
Steel Dynamics Shatters Records in Q3 2026 If there was any doubt about Steel Dynamics' ability to ride the waves in the steel and aluminum market, the third quarter of 2026 put that to rest. With a record-breaking 3.8 million tons of steel shipped and net sales reaching a steep $6.5 billion, this isn't just business as usual—it's smashing their own ceiling. Operating...
Continue Reading
Kenneth Smith Takes Helm for Trends Int’l Expansion
Tired of the Same Old Leadership Shuffle? Here Comes Kenneth Smith Look, I’ve seen my share of execs come and go, usually dragging the same old briefcase of stale ideas. But Kenneth Smith stepping up as CEO of Trends International? Now that’s got some real teeth to it. Come May 2026, he’s the guy at the helm, and he's got one hell of a to-do list. Smith's Roadmap: A...
Continue ReadingTop 5 Most Recently Viewed Articles
Dynagas LNG Partners LP: Strong Financial Results Exposed
Key Financial Highlights for Dynagas LNG Partners LP Dynagas LNG Partners LP (NYSE: DLNG) is a leading company in the liquefied natural gas (LNG) transportation segment, recently showcasing impressive financial results for the third quarter of the year. The Partnership operates a fleet of LNG carriers, which has proven effective amid fluctuating global markets. Impressive...
Continue Reading
Duvakitug Data Highlights Promising Future for IBD Treatments
Significant Advancements in IBD Treatment Research Recent updates on the efficacy of duvakitug, a monoclonal antibody targeting TL1A developed for treating ulcerative colitis (UC) and Crohn's disease (CD), have brought new hope to the journey of managing inflammatory bowel diseases (IBD). These developments stem from comprehensive clinical data gathered in the RELIEVE...
Continue Reading
Unlocking the New User Bonus and Opportunity in Cloud Mining
Exciting New User Promotions from JAMINING Mining JAMINING Mining, a prominent player in the cloud mining arena, has launched a special promotion aimed at new users. This initiative is a golden opportunity for those wishing to explore the world of cryptocurrency mining without facing high entry barriers. New users can enjoy a $100 bonus simply by signing up, enabling them...
Continue Reading
VEON Welcomes Sebastian Rice as New General Counsel in 2026
VEON Appoints New General Counsel for Future Growth In an exciting development for the digital operator, VEON Ltd. (Nasdaq: VEON) has announced the appointment of Sebastian Rice as General Counsel, starting January 1, 2026. This strategic move comes as the company continues to evolve and expand its presence in the dynamic digital landscape. Catalyst for Change: Vitaly...
Continue Reading
Ten-Year Journey of Investing in Equinix: Returns Explored
Equinix's Amazing Growth in the Last Decade Equinix (NASDAQ: EQIX) has proven to be a remarkable investment over the last ten years, significantly outperforming the broader market. Holding a consistent annualized return of 15.78%, it has outpaced the market by 4.49%. This solid performance showcases the strength which has allowed Equinix to achieve a robust market...
Continue Reading